Author + information
Angiotensin-converting enzyme 2 (ACE2) is an ACE homolog that converts angiotensin II (AngII) into angiotensin-(1-7) [Ang-(1-7)]. The tumor necrosis factor α (TNF-α), interleukin-1β, and interleukin-6 are plasma inflammatory cytokines that influence hypertension and chronic heart failure (CHF). However, the relationship between soluble ACE2 (sACE2), Anti-ACE2, Ang-(1-7) and the plasma inflammatory cytokines during the development of CHF remains unclear.
A total of 135 patients with CHF were enrolled in this study (63 males and 72 females, with LVEF (left ventricular ejection fraction) < 50%). The height and weight of each patient were measured to calculate the body mass index (BMI) of each patient. The plasma concentrations of the N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured based on their immunofluorescence. The patients were divided into four groups according to the quartiles of the NT-proBNP levels. The plasma concentrations of sACE2, anti-ACE2, Ang-(1-7), and TNF-α were measured by an enzyme-linked immunosorbent assay.
The plasma ACE2, anti-ACE2, Ang-(1-7), and TNF-α levels in CHF patients increased with the increasing NT-proBNP levels (P < 0.01). The plasma sACE2, anti-ACE2, Ang-(1-7), and TNF-α levels were positively correlated with the NT-proBNP levels (r = 0.587, r = 0.949, r = 0.614, and r = 0.711, respectively; P < 0.01). Multiple linear regression analysis showed that TNF-α, Ang-(1-7) and LVEF are independent predictors for NT-proBNP in patients with CHF.
The plasma sACE2, anti-ACE2, Ang-(1-7), and TNF-α levels increased in CHF patients as their NT-proBNP levels increased. The simultaneous detection of these markers is significant for diagnosing patients with CHF.